THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
How is your lab performing FMR1 gene testing?
Use the kit referenced in over 30 peer-reviewed publications and used in over 200 laboratories around the world. Asuragen’s AmplideX® PCR/CE FMR1 Reagents are globally recognised as best-in-class for the assessment of CGG repeats in the FMR1 gene.
AmplideX PCR/CE FMR1 Kit is an in vitro diagnostic (IVD) device for use in clinical laboratories for the detection of the CGG repeats in the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene. The device is intended to aid in the diagnosis of fragile X syndrome and fragile X-associated disorders, e.g. tremor and ataxia syndrome (FX-TAS) and primary ovarian insufficiency (FXPOI), through the determination of CGG repeat length up to 200 CGG and detection of alleles greater than 200 CGG. The kit provides a PCR-only approach based on Triplet Repeat Primed PCR (TP-PCR) design to reliably amplify and detect all alleles including Full Mutations.
AmplideX PCR/CE FMR1 Kit has created an easy-to-use, accessible, high-performance method for laboratories to reliably analyze CGG repeats and detect interrupting AGG sequences in the FMR1 gene.
Reduced Complexity
Ease-of-analysis of the FMR1 gene has been simplified through:
- Implementation of proprietary PCR solution for amplifying GC-rich regions
- Automation of result calling using AmplideX PCR/CE FMR1 Reporter
Optimized Workflow
Valuable operator hands-on time has been significantly reduced through:
- Direct injection of PCR products (no PCR clean up) in to Capillary Electrophoresis platforms
- Decreased need for Southern blot analysis (up to 50 fold)
- End-to-end solution for FMR1 analysis including all necessary reagents and software
Quality Performance
Performing FMR1 Analysis with Greater Sensitivity and Accuracy:
- Detection of all allele expansions, including low abundance full mutation size mosaics with up to at least 1300 CGG repeats
- Up to 875 fold more sensitive than Southern blot1
- Resolution of female homozygous and heterozygous samples and indication of interrupting AGG sequences
- Proven performance as indicated by more than 30 peer-reviewed publications
